Compare RM & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RM | FHTX |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.4M | 332.2M |
| IPO Year | 2011 | 2020 |
| Metric | RM | FHTX |
|---|---|---|
| Price | $32.32 | $5.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $30.00 | $11.71 |
| AVG Volume (30 Days) | 51.5K | ★ 103.0K |
| Earning Date | 05-06-2026 | 04-14-2026 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | 7.49 | ★ 32.48 |
| EPS | ★ 4.45 | N/A |
| Revenue | ★ $645,598,000.00 | $22,602,000.00 |
| Revenue This Year | $12.83 | $40.87 |
| Revenue Next Year | $7.93 | $11.27 |
| P/E Ratio | $7.23 | ★ N/A |
| Revenue Growth | ★ 9.70 | N/A |
| 52 Week Low | $25.41 | $2.94 |
| 52 Week High | $46.00 | $6.95 |
| Indicator | RM | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.12 | 46.73 |
| Support Level | $30.85 | $4.44 |
| Resistance Level | $35.30 | $5.85 |
| Average True Range (ATR) | 1.46 | 0.33 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 24.31 | 39.43 |
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.